ArticleGynecologic oncology reports2026
Real-world demographics and survival outcomes of patients in England with advanced or recurrent endometrial cancer by mismatch repair status.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03981796 (A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Real-world data on the impact of mismatch repair (MMR) status in patients with advanced/recurrent endometrial cancer (A/R EC) are limited. England's National Disease Registration Service data were used to characterize outcomes by MMR status in patients with A/R EC potentially eligible for frontline immune-checkpoint inhibitor (ICI) treatment in addition to chemotherapy. Methods: Patients in this noninterventional, retrospective study were diagnosed with A/R EC between 2019 and 2021; received frontline chemotherapy; and met inclusion/exclusion criteria for the phase 3 RUBY trial (NCT03981796). Demographics, disease characteristics, and treatment patterns were reported. Overall survival (OS) and time-to-next-treatment (TTNT) were evaluated from initiation of frontline chemotherapy using Kaplan-Meier methodology. Results: Among 1452 ICI-eligible patients, 711 had MMR test results. Of these, 158 patients had MMR deficient (dMMR) tumors, and 547 had MMR proficient (MMRp) tumors. The dMMR cohort was younger (median, 64.4 years) with a larger percentage of endometrioid tumors (79.7%) than the MMRp (68.2 years and 40.8%, respectively) and untested cohorts (68.6 years and 41.2%, respectively). Median OS and TTNT were not reached in the dMMR cohort (median follow-up, 25.4 months); 34.6 (95% CI, 28.9-42.6) and 18.2 (95% CI, 15.3-22.1) months, respectively, in the MMRp cohort (median follow-up, 23.4 months); and 37.2 (95% CI, 27.4-45.9) and 18.2 (95% CI, 15.4-22.7) months, respectively, in the untested cohort (median follow-up, 24.3 months). Conclusion: In this real-world study, 51% of patients lacked MMR test results, reflecting the need for improved testing awareness. Among those tested, overall outcomes support the need for more effective frontline regimens to treat A/R EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.